ClinicalTrials.gg
RecruitingNCT06677229eSpineUpdated Sep 9, 2025

Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

A Phase 1/2 interventional study of Eletriptan HBr 40 mg in Acute Spinal Cord Injury (SCI), sponsored by Technophage, SA. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Technophage, SA · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Planned enrollment
29th of 55
28 · median 30
Started
2025
with 4 others
Phase 1/2
7 of 59
2 open now
Primary completion
2026-12
later than 7 of 12 live
Registered
48th of 59
by date

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 29th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 7 of the 12 other live ones, and was the 48th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

Technophage identified a promising compound, Eletriptan hydrobromide, that intends to use as a repurposed drug, for the treatment of acute spinal cord injury (SCI) in human subjects. Eletriptan hydrobromide is a well characterized molecule, that has been clinically available for over two decades for the treatment of migraines. It presents a good and manageable safety profile, including for the regimen selected for this trial, and it is generally well tolerated, with minimal side effects. This is an important consideration to have when using repurposed drugs for the treatment of other indications. Technophage believes that the preclinical data collected, in combination with the acceptable safety profile of Eletriptan hydrobromide, support its use as a repurposed drug for the treatment of SCI in humans.

Read the detailed description

Eletriptan hydrobromide (HBr) is a second-generation serotonin (5-HT) receptor agonist with high affinity for 5-HT1B, 5-HT1D and 5-HT1F receptors approved for the acute treatment of the headache phase of migraine attacks, with or without aura. 5-HT is a monoamine neurotransmitter synthesized in several subpopulations of brainstem neurons and plays an important role in vertebrate locomotion. Following spinal cord injury (SCI) there is a disruption of descending serotonergic projections to spinal motor areas, which results in a subsequent 5-HT depletion, 5-HT transporter dysregulation, as well as elevated expression, hyper-sensitivity and/or constitutive auto-activation of specific 5-HT receptors. Technophage identified a new possible therapeutic indication for Eletriptan HBr, showing its locomotor recovery properties in two different animal models of injury. Based on preclinical findings, Technophage intends to test Eletriptan HBr in the clinical environment, as a repurposed drug, for the treatment of acute SCI in human subjects.

03

Conditions studied

  • Acute Spinal Cord Injury (SCI)

Keywords

  • acute spinal cord injury
  • TZ-161
  • Eletriptan Hydrobromide
  • Eletriptan HBr
  • serotonin receptor
  • 5-HT receptor
  • Relert
  • Relpax
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18-65 years old.
  2. Subjects with clinical diagnosis of acute SCI that comply with the following:

    1. Injury located on the thoracic region (T1 to T12).
    2. With clinical suspicion of a single traumatic (contusion) lesion.
    3. AIS grade of grade B, C or D with a motor score less than or equal to 3 in at least one key muscle of a lower limb.
    4. Ability to perform injury-to-drug administration ≤ 24 hours after SCI.
  3. Subjects willing and able to provide an .
  4. Subjects willing and able to complete the study and comply with instructions. The use of Relert in the elderly is not recommended, due to the fact that the safety and effectiveness of Eletriptan HBr in patients over 65 years of age had not been systematically evaluated, as a consequence of the small number of patients in this age group in clinical trials.

Exclusion criteria

Exclusion Criteria:

  1. Clinical or imaging suspicion of multi-lesion or extra-thoracic contusions on diagnostic CT scan and on MRI at 48H*.
  2. Subjects in coma or with significant cognitive impairment in the opinion of the investigator.
  3. Subjects presenting mechanical ventilation dependence.
  4. Subjects with past medical history of any - structural - neurological disorder of the central or peripheral nervous system, including past spinal cord injury. Furthermore, subjects with spine/bone-related medical history (prior to SCI) that in the opinion of the investigator are not yet resolved or previous lesions that are located in the same area of the study SCI should also be excluded.
  5. Subjects with dysphagia or inability to swallow tablets.
  6. Women who are breastfeeding or who are pregnant. Pregnancy to be excluded during screening by presence of a negative blood pregnancy test.
  7. Subjects with active , or malignancy in the last 5 years if subject is currently undergoing treatment with prohibited medication.
  8. Subjects that have recently used Eletriptan HBr (within the last 24h).
  9. Subjects presenting abnormalities (Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders) at screening.
  10. Subjects presenting any , special warnings, and precautions regarding IMP administration, as per described in the SmPC of Eletriptan HBr:

    1. Ischemic CAD, such as angina pectoris, history of myocardial infarction, and documented silent ischemia, or coronary artery vasospasm, including Prinzmetal's angina.
    2. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.
    3. History of stroke, , or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke.
    4. Peripheral vascular disease.
    5. Ischemic bowel disease.
    6. Uncontrolled hypertension.
    7. Recent use (i.e., within 24 hours) of serotonin receptor agonists
    8. Coadministration with SSRIs, SNRIs, TCAs, and MAO due to risk of serotonin syndrome.
    9. Recent use (i.e., within 24 hours) of drugs containing ergotamine or ergot-like substances (such as dihydroergotamine or methysergide)
    10. to IMP and its (angioedema and anaphylaxis seen).
  11. The following medications and/or substances are not allowed due to potential interaction with Eletriptan HBr or inhibition of the system (recent use, i.e., within at least 72 hours):

    1. Cimetidine; ketoconazole; itraconazole; fluconazole, erythromycin; clarithromycin, troleandomycin, verapamil, and MAO inhibitors [such as isocarboxazid (Marplan), phenelzine sulfate (Nardil), tranylcypromine (Parmate), selegiline (Emsam)], pioglitazone, and valerian.
    2. Antiretrovirals - such as ritonavir, indinavir, nelfinavir, efavirenz and nevirapine.
    3. Other prohibited concomitant medications include haloperidol, trazodone, triazolam, nefazodone, diltiazem, carbamazepine, phenytoin, oxcarbazepine, and phenobarbital.
    4. St. John's Wort (Hypericum perforatum).
  12. Subjects with known liver disease (except for A) or severe hepatic impairment.
  13. Subjects with known renal disease or severe renal impairment - exclude if below 50 ml/min.
  14. Subjects that have participated in any other study in the last 3 months or plan to participate in another study at any time during this clinical trial.
  15. Subjects that have foreign magnetic metal bodies or other conditions that render them unable to perform MRI.
  16. Any other issue that, in the opinion of the investigator, makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Experimental Arm Randomized to IMP (Eletriptan HBr) + SOC

    Drug: Eletriptan HBr 40 mg

  • No intervention
    Control Arm after SCI Randomized to SOC

Interventions

  • DrugEletriptanStudies of EletriptanEletriptan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.

06

What researchers measure

Primary outcomes

  1. Adverse effects

    Incidence of treatment-emergent AEs and treatment-emergent SAEs

    Time frame: Between Day 1 and Month 6 in IMP plus SOC compared to SOC alone

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Aug 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677229
Lead sponsor
Technophage, SA
Collaborators
VectorB2B
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Aug 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 9, 2025

Study contacts

Sofia Corte-Real
Contact
scortereal@technophage.pt
+351 215943993
Margarida Barreto
Contact
mbarreto@technophage.pt
+351 215943993

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eletriptan

Start the discussion